Discontinued — last reported Q1 '26
Business Segments · Accounts Receivable, Credit Loss Expense (Reversal)
U.S. Pharmaceutical — Accounts Receivable, Credit Loss Expense (Reversal)
McKesson U.S. Pharmaceutical — Accounts Receivable, Credit Loss Expense (Reversal) increased by 146.2% to $189.00M in Q2 2025 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementSegment
CategoryRisk
SignalLower is better
VolatilityModerate
First reportedQ2 2024
Last reportedQ1 2026Aug 6, 2025
Rolls up toProvision for Credit Losses
How to read this metric
A reversal or low expense indicates strong customer credit quality and effective accounts receivable management.
Detailed definition
Reflects the net impact of provisions for bad debt or the reversal of previously recorded credit losses within the U.S....
Peer comparison
Standard metric for evaluating credit risk management in B2B distribution industries.
Metric ID:
mck_segment_u_s_pharmaceutical_accounts_receivable_credit_loss_expense_reversalHistorical Data
5 periods
| Q2 '24 | Q3 '24 | Q2 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|
| Value | $210.00M | $515.00M | $203.00M | -$409.00M | $189.00M |
| QoQ Change | — | +145.2% | -60.6% | -301.5% | +146.2% |
| YoY Change | — | — | -3.3% | — | — |
Range-$409.00M – $515.00M
CAGR-10.0%
Avg YoY Growth-3.3%
Median YoY Growth-3.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's u.s. pharmaceutical — accounts receivable, credit loss expense (reversal)?
- McKesson (MCK) reported u.s. pharmaceutical — accounts receivable, credit loss expense (reversal) of $189.00M in Q2 2025.
- What does u.s. pharmaceutical — accounts receivable, credit loss expense (reversal) mean?
- The net cost or recovery related to uncollectible customer payments in the segment.